Private equity firm TPG is exploring a sale of Immucor, the maker of tests that screen blood before transfusions and organ transplants.
The diagnostic equipment manufacturer could fetch more than $2bn in a sale, the people said. While deliberations are ongoing, discussions remain at an early stage and TPG could opt to keep the company longer.
In July 2011, Immucor agreed to go private and sell itself to TPG for $1.97bn. Since then the Georgia-based company has made multiple add-on acquisitions including Sentilus Inc. and Organ-i Inc.
Read more: Yahoo Finance
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.